nach oben

Die Ophthalmologie

Erschienen in:

01.12.2013 | Leitthema

Medikamentöse Glaukomtherapie

Welche Lehren können wir aus den großen klinischen Studien ziehen?

verfasst von: Prof. Dr. A.G.M. Jünemann, F.E.B.O., C. Huchzermeyer, R. Rejdak

Erschienen in: Die Ophthalmologie | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die großen prospektiven multizentrischen randomisierten kontrollierten klinischen Studien (RCTs) Ocular Hypertension Glaucoma Treatment Study (OHTS), Early Manifest Glaucoma Trial (EMGT), Advanced Glaucoma Intervention Study (AGIS), Collaborative Initial Glaucoma Treatment Study (CITGS) und Collaborative Normal Tension Glaucoma Study (CNGTS) werden häufig als Meilensteine des Glaukommanagements bezeichnet, da ihre Ergebnisse die Evidenz für zahlreiche therapeutische Entscheidungen in der Praxis liefern. Die Studien bestätigen den bereits bestehenden Konsens, dass die prozentuale Senkung des Augeninnendrucks das Risiko der Glaukomprogression über das gesamte Glaukomspektrum von der okulären Hypertension bis zum fortgeschrittenen Glaukom reduziert. Darüber hinaus kann durch die Identifizierung neuer Risikofaktoren das Risiko der Entwicklung eines Gesichtsfeldausfalls oder seiner Progression mit größerer Präzision bestimmt werden. Die großen Studien haben unser Verständnis der Glaukome und ihrer Behandlung weiterentwickelt und eine Brücke zwischen konsensusbasierten und evidenzbasierten Entscheidungen geschlagen hat. Für die Übertragung ihrer Ergebnisse in den klinischen Alltag ist jedoch eine adäquate und akkurate Interpretation unabdingbar.

European Glaucoma Society (2008) Terminologie und Handlungsrichtlinien für die Glaukome, 3. Aufl. http://www.eugs.org (Editrice Dogma S.r.L.)

Laqueur L (1909) Geschichte meiner Glaukomerkrankung. Klin Monatsbl Augenheilkd 47:639–646

Laqueur L (1876) Ueber eine neue therapeutische Verwendung des Physostigmin. In: Centralblatt für die medicin. Wissenschaften, 14. Jg. A. Hirschwald, Berlin, S 421–422

Rossetti L, Marchetti I, Orzalesi N et al (1993) Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? Arch Ophthalmol 111:96–103PubMedCrossRef

Steinmann WC, Wilson RP (2001) Yearbook of ophthalmology. CV Mosby, St. Louis

Stehbens WE (1993) Variance and dissent: the quality of epidemiological data in coronary heart disease and atherosclerosis. J Clin Epidemiol 46:1337–1346PubMedCrossRef

Werko L (1976) Risk factors and coronary heart disease – facts or fancy? Am Heart J 91:87–98PubMedCrossRef

Kass MA, Heuer DK, Higginbotham EJ et al (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701–713PubMedCrossRef

Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268–1279PubMedCrossRef

10.

AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:490–491CrossRef

11.

Lichter PR, Musch DC, Gillespie BW et al (2001) Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108:1943–1953PubMedCrossRef

12.

Gordon MO, Beiser JA, Brandt JD et al (2002) The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol 120:714–720PubMedCrossRef

13.

Leske MC, Heijl A, Hussein M et al (2003) Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121:48–56PubMedCrossRef

14.

Leske MC, Heijl A, Hyman L et al (2007) Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 114:1965–1972PubMedCrossRef

15.

Collaborative Normal-Tension Glaucoma Study Group (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126:498–505CrossRef

16.

Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487–497CrossRef

17.

The European Glaucoma Prevention Study (EGPS) Group (2005) Results of the European Glaucoma Prevention Study. Ophthalmology 112:366–375CrossRef

18.

Wilson MR, Kosoko O, Cowan CL Jr et al (2002) Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 34:399–405CrossRef

19.

Heijl A, Bengtsson B, Hyman L et al (2009) Natural history of open-angle glaucoma. Ophthalmology 116:2271–2276PubMedCrossRef

20.

Hyman L, Heijl A, Leske MC et al (2010) Natural history of intraocular pressure in the early manifest glaucoma trial: a 6-year follow-up. Arch Ophthalmol 128:601–607PubMedCrossRef

21.

AGIS investigators (1994) Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology 101:1445–1455CrossRef

22.

Higginbotham EJ, Gordon MO, Beiser JA et al (2004) The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 122:813–820PubMedCrossRef

23.

o A (1998) The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 105:1146–1164CrossRef

24.

The AGIS Investigators (2001) The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol 132:311–320CrossRef

25.

Schwartz AL, Love DC, Schwartz MA (1985) Long-term followup of argon laser trabeculoplasty for uncontrolled open-angle glaucoma. Arch Ophthalmol 103:1482–1484PubMedCrossRef

26.

Panarelli JF, Banitt MR, Sidoti PA et al (2013) Clinical impact of 8 prospective, randomized, multicenter glaucoma trials. J Glaucoma [Epub ahead of print]

27.

Musch D, Lichter P, Guire K et al (1999) The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 106:653–662PubMedCrossRef

28.

Thorburn W (1978) The accuracy of clinical applanation tonometry. Acta Ophthalmol 56:1–55CrossRef

29.

Phelps CD, Phelps GK (1976) Measurement of intraocular pressure: a study of its reproducibility. Albrecht Von Graefes Arch Klin Exp Ophthalmol 198:39–43PubMedCrossRef

30.

Rosentreter A, Neuburger M, Jordan JF et al (2011) Einflussgrößen auf die Applanationstonometrie – ein praxisorientierter Überblick. Klin Monatsbl Augenheilkd 228:109–113PubMedCrossRef

31.

Doughty MJ, Jonuscheit S (2010) The orbscan acoustic (correction) factor for central corneal thickness measures of normal human corneas. Eye Contact Lens 36:106–115PubMedCrossRef

32.

Ocular Hypertension Treatment Study Group, European Glaucoma Prevention Study Group, Gordon MO et al (2007) Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 114:10–19CrossRef

33.

European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N et al (2007) Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 114:3–9CrossRef

34.

Velten IM, Bergua A, Horn FK et al (2000) Central corneal thickness in normal eyes, patients with ocular hypertension, normal-pressure and open-angle glaucomas – a clinical study. Klin Monatsbl Augenheilkd 217:219–224PubMedCrossRef

35.

Quigley HA, Dunkelberger GR, Green WR (1989) Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 107:453–464PubMed

36.

Horn FK, Mardin CY, Laemmer R et al (2009) Correlation between local glaucomatous visual field defects and loss of nerve fiber layer thickness measured with polarimetry and spectral domain OCT. Invest Ophthalmol Vis Sci 50:1971–1977PubMedCrossRef

37.

Jonas JB, Schmidt AM, Müller-Bergh JA et al (1992) Human optic nerve fiber count and optic disc size. Invest Ophthalmol Vis Sci 33:2012–2018PubMed

38.

Frisén L (1991) High-pass resolution perimetry and age-related loss of visual pathway neurons. Acta Ophthalmol (Copenh) 69:511–515

39.

Repka MX, Quigley HA (19899) The effect of age on normal human optic nerve fiber number and diameter. Ophthalmology 96:26–32CrossRef

40.

Leske MC, Heijl A, Hyman L, Bengtsson B (1999) Early manifest glaucoma trial: design and baseline data. Ophthalmology 106:2144–2153PubMedCrossRef

41.

Gordon MO, Kass MA (1999) The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 117:573–583PubMedCrossRef

42.

Schulzer M (1992) Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology 99:1468–1470PubMedCrossRef

43.

Miglior S, Zeyen T, Pfeiffer N et al (2005) Results of the European Glaucoma Prevention Study. Ophthalmology 112:366–375PubMedCrossRef

44.

Heijl A, Bengtsson B, Chauhan BC et al (2008) A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology 115:1557–1565PubMedCrossRef

45.

Keltner JL, Johnson CA, Quigg JM et al (2000) Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol 118:1187–1194PubMedCrossRef

46.

AGIS Investigators (2001) The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy. Arch Ophthalmol 119:1771–1779CrossRef

47.

Musch DC, Gillespie BW, Niziol LM et al (2006) Cataract extraction in the collaborative initial glaucoma treatment study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. Arch Ophthalmol 124:1694–1700PubMedCrossRef

48.

Jonas JB, Budde WM (2000) Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects. Prog Retin Eye Res 19:1–40PubMedCrossRef

49.

Zangwill LM, Weinreb RN, Berry CC et al (2004) The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors. Am J Ophthalmol 137:219–227PubMedCrossRef

50.

Weinreb RN, Zangwill LM, Jain S et al (2010) Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to the Ocular Hypertension Treatment Study. Ophthalmology 117:1674–1683PubMedCrossRef

51.

Zangwill LM, Jain S, Dirkes K et al (2013) The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Am J Ophthalmol 155:971–982PubMedCrossRef

52.

Wessel JM, Horn FK, Tornow RP et al (2013) Longitudinal analysis of progression in glaucoma using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 54:3613–3620PubMedCrossRef

53.

Armaly MF (1969) Interpretation of tonometry and ophthalmoscopy. Invest Opthalmol 8:105–124

54.

Caprioli J, Coleman AL (2008) Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 115:1123–1129PubMedCrossRef

55.

Bergea B, Bodin L, Svedbergh B (1999) Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 106:997–1004PubMedCrossRef

56.

Asrani S, Zeimer R, Wilensky J et al (2000) Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9:134–142PubMedCrossRef

57.

Lee PP, Walt JW, Rosenblatt LC et al (2007) Association between intraocular pressure variation and glaucoma progression: data from a united states chart review. Am J Ophthalmol 144:901–907PubMedCrossRef

58.

Medeiros FA, Weinreb RN, Zangwill LM et al (2008) Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology 115:934–940PubMedCentralPubMedCrossRef

59.

Gao F, Miller JP, Miglior S et al (2011) A joint model for prognostic effect of biomarker variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). JP J Biostat 5:73–96PubMedCentralPubMed

60.

Bengtsson B, Leske MC, Hyman L et al (2007) Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 114:205–209PubMedCrossRef

61.

Bengtsson B, Heijl A (2005) Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual filed loss in highrisk ocular hypertension. Graefes Arch Clin Exp Ophthalmol 243:513–518PubMedCrossRef

62.

Musch DC, Gillespie BW, Niziol LM et al (2011) Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118:1766–1773PubMedCentralPubMedCrossRef

63.

De Moraes CGV, Juthani VJ, Liebmann JM et al (2011) Risk factors for visual field progession in treated glaucoma. Arch Ophthalmol 129:562–568

64.

Martus P, Stroux A, Budde WM et al (2005) Predictive factors for progressive optic nerve damage in various types of chronic open-angle glaucoma. Am J Ophthalmol 139:999–1009PubMedCrossRef

65.

Nouri-Mahdavi K, Hoffman D, Coleman AL et al (2004) Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111:1627–1635PubMedCrossRef

66.

Ekström C (1993) Elevated intraocular pressure and pseudoexfoliation of the lens capsule as risk factors for chronic open-angle glaucoma. A population-based five-year follow-up study. Acta Ophthalmol (Copenh) 71:189–195

67.

Aström S, Stenlund H, Lindén C (2007) Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II. Results after 21 years of follow-up. Acta Ophthalmol Scand 85:832–837PubMedCrossRef

68.

Jeng SM, Karger RA, Hodge DO et al (2007) The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma 16:117–121PubMedCrossRef

69.

Jünemann A (2012) Diagnostik und Therapie des PEX-Glaukoms. Ophthalmologe 109:962–975PubMedCrossRef

70.

Grodum K, Heijl A, Bengtsson B (2005) Risk of glaucoma in ocular hypertension with and without pseudoexfoliation. Ophthalmology 112:386–390PubMedCrossRef

71.

Landers J, Martin K, Sarkies N et al (2012) A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology 119:694–702PubMedCrossRef

72.

Singh K, Shrivastava A (2008) Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care. Surv Ophthalmol 53(Suppl 1):S33–S38PubMedCrossRef

73.

Gordon MO, Torri V, Miglior S et al (2007) Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 114:10–19PubMedCrossRef

74.

Coleman AL (2002) Applying evidence-based medicine in ophthalmic practice. Am J Ophthalmol 134:599–601PubMedCrossRef

75.

Stürmer J (2011) Argumente gegen eine drucksenkende Behandlung der okulären Hyperension. Ophthalmologe 108:1006–1010PubMedCrossRef

76.

Kass MA, Gordon MO, Gao F et al (2010) Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 128:276–287PubMedCrossRef

77.

Velten IM, Budde WM, Jünemann A (1999) Does corneal ocular „pseudo-hypertension“ exist? Klin Monatsbl Augenheilkd 215:56–58PubMedCrossRef

78.

Moore A, McQuay HJ (2008) Was ist die Number Needed to Treat (NNT)? Z Allg Med 84:161–164CrossRef

Titel: Medikamentöse Glaukomtherapie
Welche Lehren können wir aus den großen klinischen Studien ziehen?
verfasst von: Prof. Dr. A.G.M. Jünemann, F.E.B.O.
C. Huchzermeyer
R. Rejdak
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Die Ophthalmologie / Ausgabe 12/2013
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-012-2671-3

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Medikamentöse Glaukomtherapie

Welche Lehren können wir aus den großen klinischen Studien ziehen?

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2013

Anlage versus Umwelt

Glaukom und trockenes Auge

Akanthamöbenkeratitis

Charakteristische Bewegungsstörungen bei myasthenischen Augenmuskellähmungen

Was hast du für große Augen?

Aderhaut-Netzhaut-Kolobom und auffällige Fazies bei einem 16-jährigen Mädchen

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde